Oral Answers to Questions

Debate between Lord Willetts and David Rutley

Thursday 7th February 2013 Commons Chamber

[The Minister for Universities and Science (Mr David Willetts)]

Our life sciences strategy, launched by the Prime Minister, has already triggered more than £1 billion of business investment in life sciences. That is good for growth and good for the NHS.

[David Rutley]

As my right hon. Friend is aware, Macclesfield and north-east Cheshire are well known for their strong base in life sciences skills and the economic contribution of companies such as AstraZeneca. In the light of that, what further steps is he taking to encourage investment in the north-west, and in north-east Cheshire in particular?

[Mr Willetts]

I pay tribute to the work of my hon. Friend, and I recall visiting the AstraZeneca facility at Alderley park with him last year. There is a very strong life sciences cluster in the north-west. We are supporting it with extra investment in the new Manchester cancer research centre and in the Manchester collaborative centre for information research.

Oral Answers to Questions

Debate between Lord Willetts and David Rutley

Thursday 20th December 2012 Commons Chamber

[David Rutley (Macclesfield) (Con)]

11. What support his Department is giving to the life sciences sector.

[The Minister for Universities and Science (Mr David Willetts)]

Last week, the Prime Minister launched the “One Year On” report for our life sciences strategy, which included a new commitment to sequence 100,000 genomes. In the autumn statement, the Chancellor announced an additional £100 million for life sciences research and, in the past year, more than £1 billion of private sector investment has been attracted to the UK on the back of Government initiatives for the life sciences. We are therefore succeeding in creating the right environment to attract global life sciences investment.

[David Rutley]

I welcome the Government’s progress report, “Strategy for UK Life Sciences—One Year On”, and the Minister’s strong support for this vital sector. Given the critical contribution of life sciences and pharmaceuticals to Macclesfield’s local economy, what plans does he have to build on this important momentum in the year ahead?

[Mr Willetts]

We need to do more and we can do more. We are going to work closely with British businesses, including AstraZeneca, which I remember visiting with my hon. Friend in his constituency earlier this year. That company has received a conditional offer through round 3 of the regional growth fund. We are continuing to back this very important, internationally competitive industry.

Oral Answers to Questions

Debate between Lord Willetts and David Rutley

Thursday 8th December 2011 Commons Chamber

[David Rutley (Macclesfield) (Con)]

T3. Returning to 2011, what steps is my right hon. Friend taking to create the conditions for the pharmaceutical and life sciences sectors in the United Kingdom, including AstraZeneca in Macclesfield, to be able to compete more strongly in the global marketplace?

[Mr Willetts]

The life sciences strategy we produced earlier this week aims to rise to the challenge my hon. Friend identifies. In particular, there is an imaginative proposal under which 20 compounds that have been identified by AstraZeneca but are not currently being commercialised will be open to research by others, with a view to using them to create the medicines of the future.